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Abstract

Objectives. This study aims to evaluate the effects of methylphenidate (MPH) on eating
patterns and body mass index (BMI) in children with attention deficit/hyperactivity disorder
(ADHD). The secondary aim of this study is the comparison between weight and eating behavior
of children with ADHD undergoing an MPH treatment, and of children without ADHD.
Methods. One hundred fourty three children and adolescents who diagnosed with ADHD were
enrolled, and the effects of MPH on the eating patterns and BMI were evaluated. All participants
completed a number of tests to analyze eating patterns and clinical psychopathological profiles.
Results. Children and adolescents with ADHD had significantly higher scores on the EDE-Qeating concern, EDE-Q- shape concern, and all CPRS-RSF subscales than individuals without
ADHD (p < .05). MPH treatment was associated with a notional reduction in height-sds and
weight-sds. The results of the correlation analysis which assessed the possible contribution of the
different treatment-related factors revealed no significant correlations between MPH mean dose
[mg/(kg/d)], the duration of use (months), and the core characteristics of eating disorders except the
restraint subscale of EDE Q.
Conclusions. Our findings add to the growing research suggesting that MPH may be associated
with disordered eating behaviors. Although the literature is limited, our findings conclude that MPH
may not be associated with the reduction of growth velocity and disordered eating behaviors.
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Highlights

✓ Patients with ADHD have significantly higher scores from the EDE-Q- eating concern,
EDE-Q- shape concern and all CPRS-RSF subscales than individuals without ADHD.

Methylphenidate, eating patterns, height, weight, BMI

✓ EDE-Q shape concern and CPRS-RSF subscale scores seem to be correlated with
inattention and cognitive problems.

To cite this article: Turan S, Akay AP. The effects of stimulants on eating patterns in children
and adolescents with Attention Deficit Hyperactivity Disorder. J Mind Med Sci. 2019; 6(2): 253260. DOI: 10.22543/7674.62.P253260

*Corresponding author: Serkan Turan, Ödemiş State Hospital Department of Child and Adolescent Psychiatry,
Post code: 35750, Izmir, Turkey
E-mail: drserkanturan@icloud.com

Serkan Turan & Aynur Akay

Introduction

Materials and Methods

Attention Deficit Hyperactivity Disorder (ADHD) is
defined as a neurodevelopmental disorder that reflects the
persistence of ADHD symptoms such as inattention,
overactivity, and impulsivity across the lifespan (1).
Children with ADHD are at elevated risk of comorbid
psychopathology such as mood disorders, anxiety
disorders, substance use disorders, learning disorders, and
conduct disorders (2). Some studies also suggest a possible
link between ADHD and an increased risk of eating
disorders, specifically that eating disorders and ADHD
may share common clinical features and that ADHD rates
may increase eating disorders and/or contribute to the
seriousness of pathological eating behaviors (3).
Biederman et al. (2010) reported that girls treated for
ADHD in childhood and adolescence were 3.5 times more
likely to be diagnosed with eating disorders than girls
without ADHD in young adulthood (95% CI: 1.6-7.3) (4).
Similarly, Yoshimasu et al. found that children with
ADHD were 5.7 times more likely to have eating disorders
than those without ADHD (95% CI: 1.1-28.2) in late
adolescence, based on data from a population-based birth
cohort (5). Childhood ADHD symptoms have been
associated with the development of irregular eating
behaviors including bulimic symptoms, binge eating, and
restrictive eating in the present and subsequent period (6,
7). However, in ADHD studies with both subjective and
objective eating disorder examination instruments,
consistent results are lacking, although it should be noted
that the effects of long-term methylphenidate (MPH) on
both appetite and weight have been minimally studied. A
recently published, double-blind, drug-placebo, cross-over
design trial found improvements, using MPH compared to
placebo, in rates of binge eating cessation (8).
Decreased appetite is the most frequent adverse effect
of stimulants, but it is not necessarily related to a decrease
in height and BMI. The association between stimulants and
a delay in growth is still unclear and controversial.
Although a recent review and meta-analysis reported the
prevalence of obesity in children/adolescents with ADHD
is 40% higher than in healthy children/adolescents, a
notable side effect of MPH is thought to be growth delay
(9).
This study evaluated the effects of MPH on eating
patterns in Turkish children and adolescents with ADHD
and also in healthy controls. The secondary aim of this
study was the comparison of weight and eating behavior
patterns between children with ADHD and MPH treatment
and children without ADHD. In this context, we
hypothesized that (I) MPH and ADHD would show a
negative effect on eating patterns, and (II) would be
associated with reduction of height, weight, and body mass
index (BMI) in Turkish children and adolescents.

Study setting and subjects
We reviewed the medical records of 152 children and
adolescents (aged 6-18 years) with ADHD who received
treatment with MPH for at least 1 year at the Department
of Child and Adolescent Psychiatry at Dokuz Eylül
University Medical School. The exclusion criteria via
medical records included (I) positive history of diseases
that can suppress growth, (II) past and/or current history of
autistic spectrum disorders or mental retardation, (III) past
and/or current history of epilepsy, brain injury, and
cerebral palsy, and (IV) use of chronic medications which
could affect growth (e.g. cortisol, stimulants, mood
stabilizers). Nine participants with missing or erroneous
entries in the data collection instruments were excluded
from the study. 144 children and adolescents (aged 6-18
years) who were brought to our pediatric outpatient clinic
by parents for causes such as headaches or acute infections,
but did not meet any diagnostic criteria, formed the healthy
sample group. Data from both groups—287 cases—were
analyzed after approval was obtained from the The Dokuz
Eylul University Ethics Committee. After participiants
were informed about the aim and method of the research,
written consent was obtained.
Height, weight, and BMI measurements of ADHD
cases were obtained from hospital records. Participants
diagnosed with K-SADS-PL by blinded professionals
completed a data form containing questions regarding
sociodemographic and clinical features (data about MPH
treatment by age, duration of MPH treatment etc.),
Wechsler Intelligence Scale for Children-Revised (WISCR) and Conners Parent Rating Scale-Revised Short Form
(only for ADHD cases to support the diagnosis), and The
Eating Disorder Examination Questionnaire (EDE-Q) (all
participants). Weight, height, and BMI z-scores (age- and
gender- adjusted) were collected at baseline and final
follow-up. We also recorded weight, height, and BMI zscores of the healthy sample group (10) for statistical
comparisons.
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Assessment instruments
Sociodemographic Data Form: This form obtained
information about age, gender, education, family type,
socioeconomic level, home conditions, status of parents,
background, and family history.
Conners Parent Rating Scale-Revised Short Form
(CPRS-RSF): This form is widely used for the assessment
of the prevalence of ADHD and its effect on diagnosis and
treatment. Studies on the new version are described in the
U.S. and Canada. The validity and reliability study of the
scale were assessed by Kaner (2013) (11).
Eating Disorder Examination Questionnaire (EDE-Q):
The EDE-Q is the self-report version of the Eating
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Disorder Assessment Interview (12). In Turkish
psychometric evaluation, the internal consistency
coefficient was .93 and the test-retest reliability was .91
(13).
Stastistical Analysis
Differences in all study variables were analysed using
SPSS (IBM, NY) version 22. The Shapiro–Wilk test was
used initially to ascertain that variables met the conditions
for parametric tests. Variables that did not show normal
distribution were evaluated by the Mann-Whitney U test.
In the interpretation of the variables, descriptive statistical
techniques and quantitative data analyses were used. Chisquare analysis was used to compare categorical variables
between groups. The Pearson correlation was used to
determine the direction, level, and significance of

correlations between the variables. P<0.05 was considered
statistically significant.

Results
Table 1 summarizes the main features of the
participants and the identification of the clinical
characteristics between groups. The mean age of the
patient group was 9.40 ± 2.60 and the mean age of the
control group was 9.85 ± 2.26, with no difference between
groups (t=1.544, p = 0.114). Table 1 summarizes the first
and last follow-up visit BMIs, WISC-R scores, MPH
duration of use (months), and MPH doses for ADHD cases.
No differences between groups were reported in terms of
sex, parental education level, and employment status (all
groups).

Table 1. The sociodemographic data of the ADHD patients and the control groups
ADHD

Controls

p-values

n = 143

n = 144

Age* (mean ± sds)

12.62 ± 2.44

12.85 ± 2.26

Gender, male, n (%)

118 (82.6%)

110 (79.7%)

Mother’s mean age (mean ± sds)

37.02 ± 3.44

35.41 ± 4.32

0.243

< 8 years

67 (46.85%)

73 (50.69%)

0.312

> 8 years

76 (53.15%)

71 (49.31%)

0.114

Maternal education n (%)

Employment status n (%)

0.105

Housewife

101 (70.63%)

91 (63.19%)

Worker

42 (29.37%)

53 (36.81%)

First BMI (sds)

19.26 (3.10)

19.56 (3.32)

0.324

Follow-up BMI (sds)

20.21 (2.75)

20.57 (2.91)

0.275

MPH duration of use (months) (sds)

28.15 (6.2)

MPH mean dose (mg) (sds)

25.99 (6.82)

MPH mean dose [mg/(kg/d)] (sds)

0.89(0.14)

WISC-R total score (sds)

89.45 (18.7)

86.25 (17.6)

0.315

Note: ADHD; attention deficit hyperactivity disorder, n (number of patients), sds; standard deviation score, BMI; body mass index, MPH;
methylpenidate, WISC-R; Wechsler Intelligence Scale for Children-revision, *p < 0.05; **p < 0.01.
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Table 2 summarizes the total and subscale scores of
ADHD and control subjects on the Eating Disorder
Examination Questionnaire (EDE-Q) and Conners Parent
Rating Scale-Revised Short Form (CPRS-RSF). A
significant difference was found between the two groups in

terms of EDE-Q- eating concerns, EDE-Q- shape concern,
and all CPRS-RSF subscales (p <.05). There were no
differences in other subtests between EDE-Q- weight
concern, EDE-Q- restraint, and EDE-Q- global score (p>
0.05).

Table 2. Conners Parent Rating Scale-Revised Short Form (CPRS-RSF) scores of ADHD and the control group
ADHD

Controls

n = 143

n = 144

mean
(SDS)

mean
(SDS)

EDE-Q- Global

1.02 (0.83)

0.92 (0.68)

1.716

1.153

0.250

EDE-Q- Restraint

0.74 (1.00)

0.89 (0.94)

0.482

-1.294

0.197

EDE-Q- Eating concern

1.03 (0.99)

0.73 (0.68)

15.277

2.964

0.003*

EDE-Q- Shape concern

1.24 (0.92)

1.02 (0.92)

0.016

2.001

0.046*

EDE-Q- Weight concern

1.00 (0.80)

1.03 (0.76)

0.018

-0.363

0.717

CPRS-RSF- Oppositional

7.96 (4.42)

3.40 (2.11)

67.284

10.991

<0.001**

CPRS-RSF- Cognitive Problems

9.90 (5.04)

2.92 (1.52)

18.604

15.594

<0.001**

CPRS-RSF- Hyperactivity

6.92 (3.99)

2.77 (1.25)

12.201

11.684

<0.001**

CPRS-RSF- Inattention

16.97
(7.37)

5.20 (2.84)

71.856

17.543

<0.001**

F

t

p-values

Note: ADHD; attention deficit hyperactivity disorder, n (number of patients), SDS; standard deviation score, EDE-Q; Eating Disorder
Examination Questionnaire, CPRS-RSF; Conners Parent Rating Scale-Revised Short Form, *p < 0.05; **p < 0.01.

Considering

weight-SDS

slightly above the average at follow-up (baseline height-

significantly decreased at follow-up (baseline weight-SDS
[SDS] 0.51 [1.06], follow-up: -0.21 [0.64]; p** < 0.001).

SDS [SDS]: 0.47 [1.18], follow-up: -0.20 [0.85]; p =
0.087).

Height-SDS [SDS] was also affected: 0.64 [1.13] at
baseline and -0.46 (2.25) at follow-up (p** < 0.001). There
were no significant differences in pre- and post-treatment
BMI-SDS [SDS] z scores: baseline 0.32 [1.01], follow-up:
-0.30 (2.56), p = 0.318. The effect of MPH on growth is
described in detail in Table 3, including pre- and postdata
on weight, height and BMI z-scores.

In the group of MPH children, weight was not affected
by the treatment (baseline weight-SDS [SDS]: 0.70 [2.95];
follow-up: 0.25 [2.82]; p = 0.312), and no effect was also
observed when MPH was started during adolescence. In
such cases, weight-SDS was slightly above the average at
follow-up (baseline weight-SDS [SDS]: 0.40 [1.02],
follow-up: -0.26 [1.08]; p = 0.238).

However, considering whether the patients were
children (6–12 years) or adolescents (13–18 years) when
they began medication, in the group of children, height

In the group of children, BMI was significantly affected
by the treatment (baseline BMI-SDS [SDS]: 0.46 [1.08];
follow-up: -0.21 [0.59]; p** < 0.001). This effect was not

was slightly affected by the treatment (baseline heightSDS [SDS]: 0.89 [1.12]; follow-up: -0.58 [2.40]; p* =
0.008), but this effect was not observed when MPH began
during adolescence. In those cases, height-SDS was

observed when MPH began during adolescence. In such
cases, BMI-SDS was slightly above the average at followup (baseline BMI-SDS [SDS]: 0.28 [1.04], follow-up: 0.12 [0.71]; p = 0.092) (Table 3).
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.
Table 3. Comparison of height, weight and BMI at baseline and follow up data of Methylphenidate treatment by age

Total sample (n= 143)

Children (6–12 years) (n= 63)

Baseline (T1) Follow-up (T2)

p

Adolescents (13–18 years) (n= 80)

Baseline (T1) Follow-up (T2) p

Baseline (T1) Follow-up (T2) p

Weight-SDS

0.51 (1.06)

-0.21 (0.64)

** < 0.001

0.70 (2.95)

0.25 (2.82)

0.312

0.40 (1.02)

-0.26 (1.08)

0.238

Height-SDS

0.64 (1.13)

-0.46 (2.25)

** < 0.001

0.89 (1.12)

-0.58 (2.40)

* 0.008

0.47 (1.18)

-0.20 (0.85)

0.087

BMI-SDS

0.32 (1.01)

-0.30 (2.56)

0.318

0.46 (1.08)

-0.21 (0.59) **< 0.001

0.28 (1.04)

-0.12 (0.71)

0.092

Note: BMI; body mass index, n (number of patients), SDS; standard deviation score; *p<0.05, **p<0.01. p values
from paired t-tests
Table 4 shows correlations between Eating Disorder
Examination Questionnaire (EDE-Q) subscale scores,
Conners Parent Rating Scale-Revised Short Form (CPRSRSF), Body mass index, MPH mean dose [mg/(kg/d)], and
duration of use (months) for the ADHD sample.
Correlations were significant between all CPRS-RSF
subscale scores and the scores for EDE-Q eating concern

(positive).mThe EDE-Q subscale scores correlated with
one other. A statistically significant positive correlation
was found between EDE-Q shape concern and CPRS-RSF
subscale scores assessing inattention and cognitive
problems. No correlations were found with BMI, MPH
mean dose [mg/(kg/d)], and duration of use (months)
except restraint subscale.
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Discussions
This study evaluated the effects of MPH on eating
patterns in attention deficit/hyperactivity disorder (ADHD)
children and adolescents. A secondary aim was to compare
the weight and eating behavior in children with ADHD and
MPH treatment with that of children without ADHD. We
had expected to find that individuals who take MPH for
ADHD would be more likely to show negative effects on
eating patterns. Moreover, we explored the association
between MPH and growth parameters of weight, height,
and BMI standard z-scores, but only minimal effects were
noted in our sample.
Previous research has associated ADHD with global
eating disorder pathology, restraint, eating, shape, and
weight concerns. Several mechanisms have been advanced
to explain ADHD effects on eating patterns. According to
one recent study (2018), children with ADHD may have
less control while eating and thus consume more calories
than healthy subjects. In addition, children diagnosed with
ADHD may eat more food even when they are satiated
compared to healthy subjects (14). Faster eating in children
with ADHD, the inability to focus on hunger-satiety cycles,
and the inability to perceive body stimuli may all lead to
impaired eating-feeding patterns.
Alternatively, the eating problems may reflect a
complex interaction among a number of functions,
including deterioration in executive function, eatingappetite problems, eating problems, obesity, eating
disorders (especially bulimia nervosa and binge eating
disorder), attachment and family relation problems. As
predicted, this interaction is more frequent and more
complicated in women with ADHD than in men.
Therefore, it is important to focus on the problems related
to nutrition-appetite-eating and not to overlook a possible
ADHD diagnosis, especially in female children and
adolescents, given that obesity, under-threshold eating
disorders (ADHD, bulimia nervosa and binge eating
disorder risk especially during adolescence), and manifest
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eating disorders are more common in female adolescents.
For this reason, early diagnosis and treatment are vitally
importance for those with ADHD.
Several interpretations of our results are possible. It is
well-known that ADHD may not directly cause eating
disorders but, in many cases, may cause subthreshold
eating disorders and impaired eating patterns (15).
Therefore, the associations between EDEQ and all CPRSRSF subscale scores that hint at increased disordered eating
patterns as another comorbidity in individuals with ADHD
might initially seem legitimate. However, it remains
uncertain whether the altered eating patterns that result
from MPH reflect a deliberate decision to compensate for
it, or whether the compensation response is automatic
(rather than deliberate). For example, shape and weight
concerns among these individuals are consistent with prior
research in those individuals who engage in disordered
eating behaviors and tend to have higher body image
concerns (16). In our study, there was no correlation
between the MPH mean dose [mg/(kg/d)], the duration of
use (months), and the core characteristics of eating
disorders except restraint subscale of EDE Q.
Whereas MPH raises brain synaptic dopamine, which
has been shown to induce anorexia and weight loss, it is
generally considered a safe medication. Research on
energy intake during the administration of MPH has been
limited, but studies have shown effects on body weight
and/or eating behavior that are consistent with the
hypothesis that dopamine may play a role in the
development or perpetuation of human obesity (17).
Attention deficit and impulsivity symptom clusters in
ADHD may increase the development of obesity and binge
eating. The early treatment of ADHD with
psychostimulants or atomoxetine may reduce nutritional
difficulties associated with obesity and binge eating, loss
of control while eating, and impairments in rewardmotivation systems (18).
The significant decrease in z-scores for height and
weight was observed in the overall sample, but the decline
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was not observed in all subgroups suggested in the clinical
literature (19, 20). Several possible mechanisms that might
explain the effects of MPH on height and weight include
inhibition of growth hormone, nutritional state differences,
and parental height values.
Our study focused on the effect of psychostimulants in
the different age subgroups, i.e., children (6–12 years) and
adolescents (13–18 years). In the children subgroup, height
and BMI were significantly reduced by the treatment.
Given this finding, young patients using MPH should be
closely monitored. Few studies have examined the
relationships between the age of onset, the duration, and
the growth parameters for the ADHD sample. The present
study suggests that younger age at ﬁrst stimulant use was
associated with a decline in anthropometric scores. Our
findings that there was no significant delay in the rate of
physical maturation do not align with the findings of
Gustafsson et al. (2010), which suggests that children with
ADHD are less mature at baseline as they show a rapid
maturation catch-up (21). The possible reasons for these
differences may include nutritional status or hormonal
mechanisms which can modify the relationship between
growth and physical maturation.

Limitations
Limitations of our study need to be considered.
Participants with no clinically diagnosed possible
conditions associated with growth retardation were
selected for the study sample, but differences between the
health conditions of the participants, which may affect the
anthropometric values, may have occurred. Also, we did
not evaluate parental anthropometric values, socioeconomic status, ethnicity, and genetic factors of the
ADHD group, which may have influenced our results.
Finally, we did not consider comorbid features such as
mood disorders or mental retardation that can be associated
with eating patterns. Because other medications can also
influence growth parameters; the impact of such factors
remains unknown.
Future prospective and longitudinal studies would
allow a deeper understanding of whether and how
complexities of growth parameters are affected by ADHD.

Conclusions
The current study evaluated the effects of MPH and
ADHD on eating patterns and growth patterns in Turkish
Children and Adolescents. The results may have clinical
implications for monitoring the core characteristics of
eating disorders and growth parameters in ADHD patients.
Our findings add to the growing literature regarding MPH,

eating disorders, and anthropometric values, with our
findings concluding that MPH may not be associated with
the reduction of growth velocity and disordered eating
behaviors.
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